Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 50 min ago
Peer-reviewedCC BYInternational journal of endocrinology

The Microbiota-Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders.

  1. 1Department of Physiology & Cell Biology School of Medicine University of Nevada Reno Nevada USA unlv.edu.
  2. 2Sir Salimullah Medical College Dhaka Bangladesh.
  3. 3Department of Pharmacy National Model College for Advance Learning Tribhuvan University Kathmandu Nepal tribhuvan-university.edu.np.

Abstract

The gut microbiota (GM) modulates host energy balance, glucose-lipid metabolism, and enteroendocrine signaling through metabolite-receptor axes that include short-chain fatty acids (SCFAs) acting on FFAR2/FFAR3 (GPR43/GPR41), microbially transformed bile acids signaling via FXR/TGR5, and amino-acid/choline-derived compounds such as imidazole propionate (ImP) and trimethylamine N-oxide (TMAO). These pathways regulate incretin biology (GLP-1/PYY), insulin sensitivity, hepatic glucose output, adipose lipolysis, and appetite, thereby shaping risk and progression of Type 2 diabetes mellitus (T2DM), obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and related conditions. Here, we synthesize mechanistic and translational evidence, highlight bidirectional drug-microbiome interactions (GLP-1 receptor agonists), and review interventions spanning diet, pre/probiotics, fecal microbiota transplantation (FMT), and pharmacologic targeting of bile-acid and SCFA pathways. Together, these findings support precision strategies that profile GM-metabolite signatures (e.g., SCFAs, secondary bile acids, and ImP TMAO) to guide prevention and therapy in metabolic and gastrointestinal disease.

Related

  1. Microbiota–host crosstalk in ulcerative colitis: mechanistic evidence and translational prospects for traditional Chinese medicine
    Jing Chen, Jing Du, Baoxi Mu +3
    Frontiers in pharmacologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCCrossref
  2. Disease-specific gut microbiota–metabolite–immune networks in hematologic disorders: mechanisms, causal support, and translational strategies
    Li Yi, Yuru Yuan, Xiaolong Ma +8
    Gut MicrobesPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMC
  3. Faecalibacterium prausnitzii in neurological disorders: mechanistic links and therapeutic potential along the microbiota–gut–brain axis
    Yuan Liu, Guangping Yang, Lang Su +6
    Frontiers in MicrobiologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefDOAJEurope PMCPMC
  4. Evaluating traditional Chinese medicine modulation of the gut microbiota–bile acid axis in metabolic and inflammatory diseases: mechanistic evidence and translational priorities
    Yanyan Yu, Jian Wang, Qingbao Yuan +2
    Frontiers in MicrobiologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMCPMC
  5. Gut Microbiota Signaling Axes as Candidate Therapeutic Targets in Type 2 Diabetes Mellitus: Mechanistic Crosstalk and Translational Challenges
    Yiyue Zhang, Tong Zhang, Yahong Tian +2
    Diabetes, Metabolic Syndrome and ObesityPeer-reviewedCC BY-NC 4.0Full textMolecular biology & gene regulationPMC
BibTeX
@article{akif2026microbiotametabolism,
  title = {{The Microbiota-Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders.}},
  author = {Adnan Akif and Nigar Sultana and Ishtyaque Mikrani},
  journal = {International journal of endocrinology},
  year = {2026},
  month = nov,
  doi = {10.1155/ije/7761643},
  url = {https://europepmc.org/article/MED/43011569},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - The Microbiota-Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders.
AU  - Adnan Akif
AU  - Nigar Sultana
AU  - Ishtyaque Mikrani
PY  - 2026
DA  - 2026/11/09
JO  - International journal of endocrinology
DO  - 10.1155/ije/7761643
UR  - https://europepmc.org/article/MED/43011569
AB  - The gut microbiota (GM) modulates host energy balance, glucose-lipid metabolism, and enteroendocrine signaling through metabolite-receptor axes that include short-chain fatty acids (SCFAs) acting on FFAR2/FFAR3 (GPR43/GPR41), microbially transformed bile acids signaling via FXR/TGR5, and amino-acid/choline-derived compounds such as imidazole propionate (ImP) and trimethylamine N-oxide (TMAO). These pathways regulate incretin biology (GLP-1/PYY), insulin sensitivity, hepatic glucose output, adipose lipolysis, and appetite, thereby shaping risk and progression of Type 2 diabetes mellitus (T2DM), obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and related conditions. Here, we synthesize mechanistic and translational evidence, highlight bidirectional drug-microbiome interactions (GLP-1 receptor agonists), and review interventions spanning diet, pre/probiotics, fecal microbiota transplantation (FMT), and pharmacologic targeting of bile-acid and SCFA pathways. Together, these findings support precision strategies that profile GM-metabolite signatures (e.g., SCFAs, secondary bile acids, and ImP TMAO) to guide prevention and therapy in metabolic and gastrointestinal disease.
SN  - 1687-8337
SN  - 1687-8345
ER  -